A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
about
Cancer therapies utilizing the camptothecins: a review of the in vivo literatureNovel camptothecin derivatives as topoisomerase I inhibitors.Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?
P2860
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
description
1998 nî lūn-bûn
@nan
1998 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
A phase I clinical and pharmac ...... as a 72-h continuous infusion.
@ast
A phase I clinical and pharmac ...... as a 72-h continuous infusion.
@en
type
label
A phase I clinical and pharmac ...... as a 72-h continuous infusion.
@ast
A phase I clinical and pharmac ...... as a 72-h continuous infusion.
@en
prefLabel
A phase I clinical and pharmac ...... as a 72-h continuous infusion.
@ast
A phase I clinical and pharmac ...... as a 72-h continuous infusion.
@en
P2093
P2860
P356
P1476
A phase I clinical and pharmac ...... as a 72-h continuous infusion.
@en
P2093
D Littlefield
L Paz-Ares
P2860
P2888
P304
P356
10.1038/BJC.1998.679
P407
P577
1998-11-01T00:00:00Z
P5875
P6179
1021749201